Difficulty: Medium
Average Score: 70%
Practice
A provider may consider testing for CYP2D6 variants prior to starting tamoxifen for breast cancer to:
Correct answer
A
Rationale
The correct answer is A because CYP2D6 enzyme metabolizes tamoxifen into its active form, endoxifen. Poor metabolizers of tamoxifen may have reduced efficacy and increased risk of therapeutic failure. Testing for CYP2D6 variants can help identify these individuals.
Choice B is incorrect because adverse drug reactions are not directly related to CYP2D6 metabolism. Choice C is incorrect as CYP2D6 testing does not assess for drug interactions. Choice D is incorrect as poor metabolizers may experience therapeutic failure due to reduced metabolism, not increased likelihood.
Choice B is incorrect because adverse drug reactions are not directly related to CYP2D6 metabolism. Choice C is incorrect as CYP2D6 testing does not assess for drug interactions. Choice D is incorrect as poor metabolizers may experience therapeutic failure due to reduced metabolism, not increased likelihood.